Aspirin for Testicular Cancer
(ASPIRE Trial)

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byLandon Brown, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Wake Forest University Health Sciences

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls

Eligibility Criteria

This trial is for patients with advanced germ cell tumors, including testicular cancer and certain rare embryonal tumors, who are at high risk of developing blood clots (VTE) while receiving standard chemotherapy.

Inclusion Criteria

I can swallow pills.

My cancer is confirmed as testicular or germ cell, stage IS or higher.

Written informed consent and HIPAA authorization for release of personal health information

+5 more

Exclusion Criteria

Allergy to ASA

I have had a blood clot in the past.

I am receiving chemotherapy after surgery to remove my cancer.

+2 more

Participant Groups

The study tests if low-dose acetylsalicylic acid (ASA), commonly known as aspirin, can prevent blood clots in these patients over a period of 6 months compared to past data from similar patients not given ASA.

1Treatment groups

Experimental Treatment

Group I: Low-dose aspirin (acetylsalicylic acid [ASA])Experimental Treatment1 Intervention

ASA has been shown to reduce risk of VTE. It will be self-administered, a fixed dose of ASA (81 mg) by mouth daily for 26 weeks.